Sprifermin
Also known as: AS-902330, AS902330, FGF-18 truncated form, FGF18, rhFGF-18, Sprifermin
Source Sprifermin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Sprifermin is a recombinant human FGF18 analog investigated as a disease‑modifying osteoarthritis drug administered by intra‑articular injection to promote cartilage growth.
Mechanism of Action
Binds FGFR3 on chondrocytes, stimulating proliferation and extracellular matrix production, leading to cartilage regeneration
Routes of Administration
Goals & Uses
- Cartilage thickness increase in knee osteoarthritisStructural / Disease ModifyingModerate
- Symptomatic relief of knee osteoarthritis (pain/function)SymptomaticLow
- Disease-modifying osteoarthritis drugDisease ModificationModerate
- Disease-modifying osteoarthritis drug (DMOAD)Disease ModificationModerate
Contraindications
- Active joint infection or septic arthritisInfectiousHigh
- Active malignancy or history of malignancy near jointOncologicHigh
- Known hypersensitivity to sprifermin or excipientsAllergyModerate
- Known hypersensitivity to sprifermin or FGF-18ImmunologicHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Active joint infectionInfectionHigh
Adverse Effects
- Anti-drug antibodies (immunogenicity)ImmunologicUncommon
- Injection site painLocalCommonPain at the injection site
- HeadacheNeurologicUncommonPain in the head or upper neck
- Joint effusion/swellingLocalUncommon
- Nasopharyngitis / upper respiratory infectionInfectiousUncommon
- Transient increase in inflammatory markersSystemicRare
- Injection site reactions (arthralgia, swelling, effusion)Local/musculoskeletalCommon
Drug Interactions
- Intra-articular corticosteroidsModerate
- Heparin / heparin-like compoundsLow
- Intra‑articular corticosteroidsModerate
Population Constraints
- Severe knee OA (KL grade 4)Disease SeverityRelative
- Patients with active or recent malignancyOncologicRelative
- Pediatric patientsAgeRelative
- Pregnant or breastfeeding womenReproductiveAbsolute
- Severely immunocompromised patientsImmunologicalRelative
Regulatory Status
- European UnionInvestigationalClinical trial authorization in several EU member states.
- United StatesInvestigationalUnder IND; Phase II/III trials for knee OA.
- United KingdomInvestigationalMHRA clinical trial approval.
Not approved in any major jurisdiction; currently in Phase II/III clinical trials for knee osteoarthritis.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Sprifermin?
Sprifermin is a recombinant human FGF18 analog investigated as a disease‑modifying osteoarthritis drug administered by intra‑articular injection to promote cartilage growth.
What is Sprifermin used for?
Sprifermin is educationally associated with: Cartilage thickness increase in knee osteoarthritis, Symptomatic relief of knee osteoarthritis (pain/function), Disease-modifying osteoarthritis drug, Disease-modifying osteoarthritis drug (DMOAD). Educational only — not medical advice.
How is Sprifermin administered?
Recorded routes of administration: Intra Articular.
What are the potential side effects of Sprifermin?
Reported adverse effects include: Anti-drug antibodies (immunogenicity), Injection site pain, Headache, Joint effusion/swelling, Nasopharyngitis / upper respiratory infection, Transient increase in inflammatory markers, Injection site reactions (arthralgia, swelling, effusion). This list is not exhaustive — consult a qualified clinician.
Who should avoid Sprifermin?
Recorded contraindications: Active joint infection or septic arthritis, Active malignancy or history of malignancy near joint, Known hypersensitivity to sprifermin or excipients, Known hypersensitivity to sprifermin or FGF-18, Pregnancy, Active joint infection. Consult a qualified clinician before use.